Liberation Day: AeroPace System Slashes Ventilator Time, Offering New Hope to Critically Ill
- Major Breakthrough: The AeroPace® System is proven to significantly reduce ventilator dependence for critically ill patients.
- Landmark Trial: The international RESCUE-3 trial shows AeroPace users experience an average three-day reduction in ventilator time1, 2.
- Global Recognition: Pivotal findings published in the American Journal of Respiratory and Critical Care Medicine, heralding a new era in critical care1.
EXTON, Pa., June 12, 2025 – For patients trapped in the harrowing fight for every breath, tethered to mechanical ventilators, a groundbreaking medical advancement offers a powerful new ally. Lungpacer Medical today announced that the prestigious American Journal of Respiratory and Critical Care Medicine has published the pivotal clinical trial results for its FDA-approved AeroPace® System. This landmark data confirms AeroPace’s ability to accelerate liberation from mechanical ventilation and, crucially, strengthen the diaphragm in critically-ill patients1, 2.
The RESCUE-3 trial, a robust international study spanning 48 centers across the United States and Europe, enrolled 223 adult patients who had endured at least 96 hours on mechanical ventilation and faced repeated weaning failures2, 3. The results are nothing short of transformative: patients treated with the AeroPace System alongside standard care saw remarkable improvements, including an average reduction of three ventilator days, with probabilities exceeding 97.5% compared to standard care alone.
"This robust, international trial validates what we’ve long believed – that targeted diaphragm neurostimulation can fundamentally transform outcomes for patients having difficulty weaning," declared Doug Evans, CEO of Lungpacer Medical. "The three-day reduction in ventilator time is highly meaningful for these patients who are struggling each day to breathe again on their own. Every day on the ventilator increases the risk of complications, inability to wean, and even death."
The findings, recently spotlighted at the world’s premier critical care research conference in Belfast, Northern Ireland, underscore the global significance of this innovation1, 5. "The RESCUE-3 trial represents a pivotal advancement in critical care," stated Dr. Martin Dres, a leading researcher on the trial. Dr. Ewan Goligher added, "Transvenous diaphragm neurostimulation is a groundbreaking new approach...this therapy represents an exciting and important advancement in intensive care medicine."
Approved by the FDA in December 2024, the AeroPace System targets the nerves that activate the diaphragm, effectively exercising and strengthening this vital breathing muscle1. For patients fighting to break free from prolonged ventilation, the AeroPace System isn't just a technology; it's a lifeline.
References
Stay Updated!
Get the latest biotech and pharma news delivered to your inbox.